|

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

RECRUITINGSponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Actively Recruiting
SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
Started2021-04-01
Est. completion2026-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05062421

Summary

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients aged ≥18 years.
* With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
* Who have received at least one of the doses of the study drugs.
* In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
* With at least two complete evaluations (baseline and final) of clinical variables.

Exclusion Criteria:

* Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
* Patients in whom more than 50% of the variables to be collected are missing in the data collection.

Conditions2

ArthritisArthritis, Rheumatoid

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.